Daniel T. Utzschneider
University of California, San Diego
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Daniel T. Utzschneider.
Nature Immunology | 2013
Daniel T. Utzschneider; Amandine Legat; Silvia A. Fuertes Marraco; Lucie Carrié; Immanuel F. Luescher; Daniel E. Speiser; Dietmar Zehn
During chronic infection, pathogen-specific CD8+ T cells upregulate expression of molecules such as the inhibitory surface receptor PD-1, have diminished cytokine production and are thought to undergo terminal differentiation into exhausted cells. Here we found that T cells with memory-like properties were generated during chronic infection. After transfer into naive mice, these cells robustly proliferated and controlled a viral infection. The reexpanded T cell populations continued to have the exhausted phenotype they acquired during the chronic infection. Thus, the cells underwent a form of differentiation that was stably transmitted to daughter cells. We therefore propose that during persistent infection, effector T cells stably differentiate into a state that is optimized to limit viral replication without causing overwhelming immunological pathology.
Clinical & Developmental Immunology | 2012
Selena Vigano; Daniel T. Utzschneider; Matthieu Perreau; Giuseppe Pantaleo; Dietmar Zehn; Alexandre Harari
The functional avidity is determined by exposing T-cell populations in vitro to different amounts of cognate antigen. T-cells with high functional avidity respond to low antigen doses. This in vitro measure is thought to correlate well with the in vivo effector capacity of T-cells. We here present the multifaceted factors determining and influencing the functional avidity of T-cells. We outline how changes in the functional avidity can occur over the course of an infection. This process, known as avidity maturation, can occur despite the fact that T-cells express a fixed TCR. Furthermore, examples are provided illustrating the importance of generating T-cell populations that exhibit a high functional avidity when responding to an infection or tumors. Furthermore, we discuss whether criteria based on which we evaluate an effective T-cell response to acute infections can also be applied to chronic infections such as HIV. Finally, we also focus on observations that high-avidity T-cells show higher signs of exhaustion and facilitate the emergence of virus escape variants. The review summarizes our current understanding of how this may occur as well as how T-cells of different functional avidity contribute to antiviral and anti-tumor immunity. Enhancing our knowledge in this field is relevant for tumor immunotherapy and vaccines design.
Journal of Experimental Medicine | 2016
Daniel T. Utzschneider; Francesca Alfei; Patrick Roelli; David Barras; Vijaykumar Chennupati; Stephanie Darbre; Mauro Delorenzi; Daniel D. Pinschewer; Dietmar Zehn
Using recombinant antigen variant-expressing chronic LCMV strains, Zehn and colleagues showed that amount rather than antigen strength is a key determinant of inducing a chronic infection phenotype in T cells.
Journal of Biological Chemistry | 2014
Wolfgang Skala; Daniel T. Utzschneider; Viktor Magdolen; Mekdes Debela; Shihui Guo; Charles S. Craik; Hans Brandstetter; Peter Goettig
Background: Serine proteases KLK2 and KLK3 clear the way for spermatozoa before impregnation. Results: Enzymatic assays and structures of KLK2 elucidate its catalytic action, especially when compared with conformations of similar proteases. Conclusion: Flexible loops around the active site of serine proteases open concertedly upon substrate binding. Significance: This mechanistic model will stimulate the design of pharmaceutical inhibitors. Human kallikrein-related peptidase 2 (KLK2) is a tryptic serine protease predominantly expressed in prostatic tissue and secreted into prostatic fluid, a major component of seminal fluid. Most likely it activates and complements chymotryptic KLK3 (prostate-specific antigen) in cleaving seminal clotting proteins, resulting in sperm liquefaction. KLK2 belongs to the “classical” KLKs 1–3, which share an extended 99- or kallikrein loop near their non-primed substrate binding site. Here, we report the 1.9 Å crystal structures of two KLK2-small molecule inhibitor complexes. In both structures discontinuous electron density for the 99-loop indicates that this loop is largely disordered. We provide evidence that the 99-loop is responsible for two biochemical peculiarities of KLK2, i.e. reversible inhibition by micromolar Zn2+ concentrations and permanent inactivation by autocatalytic cleavage. Indeed, several 99-loop mutants of KLK2 displayed an altered susceptibility to Zn2+, which located the Zn2+ binding site at the 99-loop/active site interface. In addition, we identified an autolysis site between residues 95e and 95f in the 99-loop, whose elimination prevented the mature enzyme from limited autolysis and irreversible inactivation. An exhaustive comparison of KLK2 with related structures revealed that in the KLK family the 99-, 148-, and 220-loop exist in open and closed conformations, allowing or preventing substrate access, which extends the concept of conformational selection in trypsin-related proteases. Taken together, our novel biochemical and structural data on KLK2 identify its 99-loop as a key player in activity regulation.
Proceedings of the National Academy of Sciences of the United States of America | 2017
Matteo Rossi; Patrik Castiglioni; Mary-Anne Hartley; Remzi Onur Eren; Florence Prevel; Chantal Desponds; Daniel T. Utzschneider; Dietmar Zehn; Maria Grazia Cusi; F. Matthew Kuhlmann; Stephen M. Beverley; Catherine Ronet; Nicolas Fasel
Significance Infection with Leishmania (Viannia) parasites can have different manifestations, ranging from localized cutaneous to disseminated and mucocutaneous leishmaniasis, that are prone to relapse after the healing. We previously described the association of the endosymbiont Leishmania RNA virus 1 (LRV1) with increased disease severity. Here, we showed that coinfection with the lymphocytic choriomeningitis virus (LCMV) or Toscana virus exacerbated the outcome of Leishmania guyanensis-induced murine leishmaniasis, favoring parasite persistence and dissemination resulting in metastasis. Both endogenous and exogenous coinfections were dependent upon type I interferon responses. Strikingly, LCMV coinfection after the healing of leishmaniasis induced disease reactivation, overriding the protective adaptive immune response. Thus, viral infections may be a significant risk factor contributing to the pathological spectrum of human leishmaniasis. The presence of the endogenous Leishmania RNA virus 1 (LRV1) replicating stably within some parasite species has been associated with the development of more severe forms of leishmaniasis and relapses after drug treatment in humans. Here, we show that the disease-exacerbatory role of LRV1 relies on type I IFN (type I IFNs) production by macrophages and signaling in vivo. Moreover, infecting mice with the LRV1-cured Leishmania guyanensis (LgyLRV1−) strain of parasites followed by type I IFN treatment increased lesion size and parasite burden, quantitatively reproducing the LRV1-bearing (LgyLRV1+) infection phenotype. This finding suggested the possibility that exogenous viral infections could likewise increase pathogenicity, which was tested by coinfecting mice with L. guyanensis and lymphocytic choriomeningitis virus (LCMV), or the sand fly-transmitted arbovirus Toscana virus (TOSV). The type I IFN antiviral response increased the pathology of L. guyanensis infection, accompanied by down-regulation of the IFN-γ receptor normally required for antileishmanial control. Further, LCMV coinfection of IFN-γ–deficient mice promoted parasite dissemination to secondary sites, reproducing the LgyLRV1+ metastatic phenotype. Remarkably, LCMV coinfection of mice that had healed from L. guyanensis infection induced reactivation of disease pathology, overriding the protective adaptive immune response. Our findings establish that type I IFN-dependent responses, arising from endogenous viral elements (dsRNA/LRV1), or exogenous coinfection with IFN-inducing viruses, are able to synergize with New World Leishmania parasites in both primary and relapse infections. Thus, viral infections likely represent a significant risk factor along with parasite and host factors, thereby contributing to the pathological spectrum of human leishmaniasis.
Journal of Experimental Medicine | 2018
Arnaud Delpoux; Rodrigo Hess Michelini; Shilpi Verma; Chen-Yen Lai; Kyla D. Omilusik; Daniel T. Utzschneider; Alec J. Redwood; Ananda W. Goldrath; Chris A. Benedict; Stephen M. Hedrick
Upon infection with an intracellular pathogen, cytotoxic CD8+ T cells develop diverse differentiation states characterized by function, localization, longevity, and the capacity for self-renewal. The program of differentiation is determined, in part, by FOXO1, a transcription factor known to integrate extrinsic input in order to specify survival, DNA repair, self-renewal, and proliferation. At issue is whether the state of T cell differentiation is specified by initial conditions of activation or is actively maintained. To study the spectrum of T cell differentiation, we have analyzed an infection with mouse cytomegalovirus, a persistent-latent virus that elicits different cytotoxic T cell responses characterized as acute resolving or inflationary. Our results show that FOXO1 is continuously required for all the phenotypic characteristics of memory-effector T cells such that with acute inactivation of the gene encoding FOXO1, T cells revert to a short-lived effector phenotype, exhibit reduced viability, and manifest characteristics of anergy.
PLOS Neglected Tropical Diseases | 2017
Patrik Castiglioni; Mary-Anne Hartley; Matteo Rossi; Florence Prevel; Chantal Desponds; Daniel T. Utzschneider; Remzi-Onur Eren; Haroun Zangger; Livia Brunner; Nicolas Collin; Dietmar Zehn; F. Matthew Kuhlmann; Stephen M. Beverley; Nicolas Fasel; Catherine Ronet
Recent studies have shown that a cytoplasmic virus called Leishmaniavirus (LRV) is present in some Leishmania species and acts as a potent innate immunogen, aggravating lesional inflammation and development in mice. In humans, the presence of LRV in Leishmania guyanensis and in L. braziliensis was significantly correlated with poor treatment response and symptomatic relapse. So far, no clinical effort has used LRV for prophylactic purposes. In this context, we designed an original vaccine strategy that targeted LRV nested in Leishmania parasites to prevent virus-related complications. To this end, C57BL/6 mice were immunized with a recombinant LRV1 Leishmania guyanensis viral capsid polypeptide formulated with a T helper 1-polarizing adjuvant. LRV1-vaccinated mice had significant reduction in lesion size and parasite load when subsequently challenged with LRV1+ Leishmania guyanensis parasites. The protection conferred by this immunization could be reproduced in naïve mice via T-cell transfer from vaccinated mice but not by serum transfer. The induction of LRV1 specific T cells secreting IFN-γ was confirmed in vaccinated mice and provided strong evidence that LRV1-specific protection arose via a cell mediated immune response against the LRV1 capsid. Our studies suggest that immunization with LRV1 capsid could be of a preventive benefit in mitigating the elevated pathology associated with LRV1 bearing Leishmania infections and possibly avoiding symptomatic relapses after an initial treatment. This novel anti-endosymbiotic vaccine strategy could be exploited to control other infectious diseases, as similar viral infections are largely prevalent across pathogenic pathogens and could consequently open new vaccine opportunities.
Immunity | 2013
Jan C. Dudda; Bruno Salaun; Yun Ji; Douglas C. Palmer; Gwennaëlle C. Monnot; Estelle Merck; Caroline Boudousquié; Daniel T. Utzschneider; Thelma M. Escobar; Rachel Perret; Stefan A. Muljo; Michael Hebeisen; Nathalie Rufer; Dietmar Zehn; Alena Donda; Nicholas P. Restifo; Werner Held; Luca Gattinoni; Pedro Romero
Neuron | 2016
Jie Jiang; Qiang Zhu; Tania F. Gendron; Shahram Saberi; Melissa McAlonis-Downes; Amanda Seelman; Jennifer E. Stauffer; Paymaan Jafar-Nejad; Kevin Drenner; Derek Schulte; Seung Chun; Shuying Sun; Shuo-Chien Ling; Brian Myers; Jeffery Engelhardt; Melanie Katz; Michael Baughn; Oleksandr Platoshyn; Martin Marsala; Andy Watt; Charles J. Heyser; M. Colin Ard; Louis De Muynck; Lillian M. Daughrity; Deborah A. Swing; Lino Tessarollo; Chris J. Jung; Arnaud Delpoux; Daniel T. Utzschneider; Stephen M. Hedrick
Nature Reviews Immunology | 2014
Daniel E. Speiser; Daniel T. Utzschneider; Susanne G. Oberle; Christian Münz; Pedro Romero; Dietmar Zehn